問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • mmhcto@gmail.com
  • Alice Huang
  • 25433535-2851
  • 104Taipei CityJhong ShanNo. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan

Recruiting Trial

221Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

589Cases

2019-01-01 - 2020-12-31

Others

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) Quadrivalent Inactivated Influenza Vaccine in Healthy Subjects Aged 6 Months Old to 35 Months Old

  • Condition/Disease

    Influenza

  • Test Drug

    AdimFlu-S Quadrivalent Inactivated Influenza Vaccine(AdimFlu-S(QIS))

Participate Sites
9Sites

Recruiting8Sites

2022-02-15 - 2024-01-25

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSV MAT

Participate Sites
5Sites

Recruiting5Sites

2019-06-01 - 2021-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2008-01-01 - 2010-01-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-09-30 - 2015-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-06-19 - 2021-06-30

Phase I/II

A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive infants.

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    ChAd155-RSV vaccine; Placebo

Participate Sites
4Sites

Terminated4Sites

2016-03-01 - 2018-10-31

Phase II

A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine

  • Condition/Disease

    Active immunization against influenza A virus H5N1 subtype

  • Test Drug

    GlaxoSmithKline (GSK) Biologicals’ Influenza A/Indonesia/05/2005 (H5N1) vaccine adjuvanted with AS03

Participate Sites
8Sites

Terminated7Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2014-10-01 - 2016-12-31

Phase III

Safety and immunogenicity study of GSK Biologicals’ MMR vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine, in healthy children 12 to 15 months of age.

  • Condition/Disease

    Measles, mumps and rubella

  • Test Drug

    Measles, mumps and rubella (MMR) vaccine live

Participate Sites
8Sites

Terminated8Sites

2014-08-08 - 2016-12-31

Phase III

急性冠心症受試者接受 Losmapimod 或安慰劑治療，比較心血管重大不良事件發生率之臨床結果試驗

  • Condition/Disease

    Acute Coronary Syndrome

  • Test Drug

    Losmapimod

Participate Sites
6Sites

Terminated6Sites

1 35 36 37 38 39 59
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB